samedan logo
 
 
 
spacer
home > ebr > winter 2003 > the proposed european approach to bolar: an appropriate adaptation of the experimental use exemption for the european community?
PUBLICATIONS
European Biopharmaceutical Review

The Proposed European Approach to BOLAR: An Appropriate Adaptation of the Experimental Use Exemption for the European Community?

The authorisation of medicinal products requires clinical trials without which therapeutic progress would be impossible. Although the safety and efficacy of new medicinal substances are first tested in vitro (the analytical test) and in tests with animals (the pharmacological-toxicological test), the therapeutic efficacy of a drug is only finally established by a trial in humans (the clinical trial). Clinical trials are usually also conducted for authorisation of well-established medicines - that is, the authorisation of generic medicinal products - for which an abridged authorisation procedure is available if the generic is 'essentially similar' to the well-established reference drug. In a judgement made on 3rd December 1998 (the 'Generics judgement'), the European Court of Justice (ECJ) held, among other things, that a medicinal product is essentially similar to an original medicinal product when (1):

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Manja Epping, Lawyer at Ashurst and Ina Gerstberger, Lawyer at Taylor Wessing

Dr Manja Epping is a qualified lawyer working in the Munich office of international law firm Ashurst. In 1990 she took a French degree (Maоtrise en droit) in international and European law. After having qualified in Germany in 1995, Manja wrote her doctoral thesis on German and international arbitration law. Since then, she has specialised in German and European intellectual property law including regulatory issues, with a particular focus on the pharmaceutical and nutraceutical industries. She is an experienced litigator and a regular speaker at conferences.


Ina Gerstberger studied Biochemistry and Law and worked as a Research Assistant at the Department of Public Law at the University of Hannover. She is now a qualified Lawyer at the Munich office of the international full-service law firm Taylor Wessing. Ina specialises in pharmaceuticals, chemistry and biotechnology patent matters and the protection of plant varieties. She also advises clients on R&D and licensing contracts. Ina has particular expertise in delimitation of pharmaceuticals, foodstuffs, medical devices and the approval of biocides, as well as unfair competition law in relation to medicinal products. She is a regular speaker at conferences.

spacer
Dr Manja Epping
spacer
spacer
spacer
Ina Gerstberger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Injection vials for vaccines for protection against Covid-19

Düsseldorf, July 02, 2020 The vaccines under development to protect against Covid-19 are, like many other drugs, filled in so-called injection or vials made of type 1 borosilicate glass, also known as vials. The large worldwide demand for vials is met by the Gerresheimer Group's plants in Europe, America and Asia, where they are manufactured to high quality standards for customers in the pharmaceutical industry. The Company has already received initial orders for vials for drugs and vaccines against Covid-19.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement